{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:31:57Z","timestamp":1792445517615,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neural involvement in the tumor microenvironment (TME) has increasingly been recognized as a regulator of cancer aggressiveness. However, its characterization in breast cancer remains a challenge due to very low nerve density in this cancer type. This study investigates the clinical relevance of cancer-medicated nerve recruitment activity in the TME of breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic and clinical data from 9017 breast cancer patients across multiple cohorts were analyzed. A Neuron Projection Guidance (NPG) score generated by GSVA of a MSigDB gene set was used to quantify nerve recruitment activity. Patients were dichotomized by cohort-specific medians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NPG score was associated with axonogenesis-related gene expressions. NPG-high tumors exhibited lower cell proliferation, indicated by less Ki67 gene expression, and less enrichment of proliferation-related Hallmark gene sets. NPG-high tumors revealed significantly lower mutational burdens and neoantigen loads, which were consistent with an immune-cold TME, characterized by lower infiltration of immune effector cells, decreased cytolytic activity, and suppressed immune-related pathways. NPG scores were higher in patients who did not achieve pathological complete response after neoadjuvant chemotherapy. Moreover, high NPG scores were associated with poorer survival. These associations were observed in triple-negative breast cancer (TNBC), but not consistently in ER+\/HER2\u2212 nor HER2+ subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings reveal a previously unrecognized tumor-neuronal cross-talk in TNBC biology, which associates with an immune-cold TME, reduced chemotherapeutic efficacy, and unfavorable clinical outcomes. Such a network has potential implications for risk stratification and therapeutic decision-making in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19932-3","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:25:50Z","timestamp":1785000350000},"page":"10425-10435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Kei","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Oshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. L.","family":"Ebos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott I.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arin","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-4241","authenticated-orcid":false,"given":"Kazuaki","family":"Takabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"8","key":"19932_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41568-025-00831-w","volume":"25","author":"M Amit","year":"2025","unstructured":"Amit M, Eichwald T, Roger A, et al. Neuro-immune cross-talk in cancer. Nat Rev Cancer. 2025;25(8):573\u201389.","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"19932_CR2","doi-asserted-by":"publisher","first-page":"dmm049729","DOI":"10.1242\/dmm.049729","volume":"16","author":"TT Le","year":"2023","unstructured":"Le TT, Oudin MJ. Understanding and modeling nerve-cancer interactions. Dis Model Mech. 2023;16(1):dmm049729.","journal-title":"Dis Model Mech."},{"issue":"7935","key":"19932_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","volume":"611","author":"M Balood","year":"2022","unstructured":"Balood M, Ahmadi M, Eichwald T, et al. Nociceptor neurons affect cancer immunosurveillance. Nature. 2022;611(7935):405\u201312.","journal-title":"Nature."},{"issue":"6","key":"19932_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/0008-5472.CAN-20-2793","volume":"81","author":"DA Silverman","year":"2021","unstructured":"Silverman DA, Martinez VK, Dougherty PM, et al. Cancer-associated neurogenesis and nerve-cancer cross-talk. Cancer Res. 2021;81(6):1431\u201340.","journal-title":"Cancer Res."},{"issue":"1","key":"19932_CR5","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1038\/s41467-018-06640-0","volume":"9","author":"M Madeo","year":"2018","unstructured":"Madeo M, Colbert PL, Vermeer DW, et al. Cancer exosomes induce tumor innervation. Nat Commun. 2018;9(1):4284.","journal-title":"Nat Commun."},{"issue":"6","key":"19932_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-18-1398","volume":"9","author":"S Faulkner","year":"2019","unstructured":"Faulkner S, Jobling P, March B, et al. Tumor neurobiology and the war of nerves in cancer. Cancer Discov. 2019;9(6):702\u201310.","journal-title":"Cancer Discov."},{"issue":"4","key":"19932_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189121","volume":"1879","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Lv ZG, Lu M, et al. Nerve-tumor crosstalk in tumor microenvironment: From tumor initiation and progression to clinical implications. Biochim Biophys Acta Rev Cancer. 2024;1879(4):189121.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"1","key":"19932_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/cancers13010152","volume":"13","author":"SL Schonkeren","year":"2021","unstructured":"Schonkeren SL, Thijssen MS, Vaes N, et al. The emerging role of nerves and glia in colorectal cancer. Cancers. 2021;13(1):152.","journal-title":"Cancers"},{"issue":"6142","key":"19932_CR9","doi-asserted-by":"publisher","first-page":"1236361","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341(6142):1236361.","journal-title":"Science."},{"issue":"6","key":"19932_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1096\/fba.2021-00147","volume":"4","author":"D Li","year":"2022","unstructured":"Li D, Hu LN, Zheng SM, et al. High nerve density in breast cancer is associated with poor patient outcome. FASEB Bioadv. 2022;4(6):391\u2013401.","journal-title":"FASEB Bioadv."},{"issue":"1","key":"19932_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12967-025-06104-2","volume":"23","author":"H Wang","year":"2025","unstructured":"Wang H, Huo R, He K, et al. Increased nerve density adversely affects outcome in colorectal cancer and denervation suppresses tumor growth. J Transl Med. 2025;23(1):112.","journal-title":"J Transl Med."},{"issue":"27","key":"19932_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000172","volume":"93","author":"D Huang","year":"2014","unstructured":"Huang D, Su S, Cui X, et al. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine. 2014;93(27):e172.","journal-title":"Medicine"},{"issue":"2","key":"19932_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2020.03.034","volume":"181","author":"M Monje","year":"2020","unstructured":"Monje M, Borniger JC, D\u2019Silva NJ, et al. Roadmap for the emerging field of cancer neuroscience. Cell. 2020;181(2):219\u201322.","journal-title":"Cell."},{"key":"19932_CR14","doi-asserted-by":"crossref","unstructured":"Bloomer H, Parker SR, Pierce AL, et al. Triple-negative breast cancer cells activate sensory neurons via TRPV1 to drive nerve outgrowth and tumor progression. bioRxiv. 2025.","DOI":"10.1101\/2025.07.22.666151"},{"issue":"1","key":"19932_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41523-022-00485-z","volume":"8","author":"TT Le","year":"2022","unstructured":"Le TT, Payne SL, Buckwald MN, et al. Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. NPJ Breast Cancer. 2022;8(1):116.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"19932_CR16","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1038\/s41598-020-60030-5","volume":"10","author":"R Tan","year":"2020","unstructured":"Tan R, Li H, Huang Z, et al. Neural functions play different roles in triple negative breast cancer (TNBC) and non-TNBC. Sci Rep. 2020;10(1):3065.","journal-title":"Sci Rep."},{"issue":"6","key":"19932_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4149\/neo_2019_190110N34","volume":"66","author":"A Spini","year":"2019","unstructured":"Spini A, Roberto G, Gini R, et al. Evidence of beta-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review. Neoplasma. 2019;66(6):963\u201370.","journal-title":"Neoplasma."},{"issue":"2","key":"19932_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100066","volume":"6","author":"R Caparica","year":"2021","unstructured":"Caparica R, Bruzzone M, Agostinetto E, et al. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open. 2021;6(2):100066.","journal-title":"ESMO Open."},{"issue":"6","key":"19932_CR19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-022-01891-7","volume":"127","author":"LL Lofling","year":"2022","unstructured":"Lofling LL, Stoer NC, Sloan EK, et al. beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer. 2022;127(6):1086\u201396.","journal-title":"Br J Cancer."},{"key":"19932_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics."},{"issue":"10","key":"19932_CR21","doi-asserted-by":"publisher","first-page":"7959","DOI":"10.1245\/s10434-025-17657-3","volume":"32","author":"M Oshi","year":"2025","unstructured":"Oshi M, Ghasemi F, Yamada A, et al. Activated hippo pathway is associated with a worse response to trastuzumab and worse survival in HER2-positive breast cancer. Ann Surg Oncol. 2025;32(10):7959\u201369.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19932_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.14740\/wjon2009","volume":"16","author":"R Vaghjiani","year":"2025","unstructured":"Vaghjiani R, Wu R, Tung KH, et al. Angiogenesis is associated with aggressive biology that counterbalances with tumor immunogenicity in hepatocellular carcinoma. World J Oncol. 2025;16(2):173\u201381.","journal-title":"World J Oncol."},{"issue":"2","key":"19932_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-022-06633-0","volume":"194","author":"M Oshi","year":"2022","unstructured":"Oshi M, Gandhi S, Yan L, et al. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. Breast Cancer Res Treat. 2022;194(2):231\u201341.","journal-title":"Breast Cancer Res Treat."},{"key":"19932_CR24","doi-asserted-by":"publisher","first-page":"1588604","DOI":"10.3389\/fmed.2025.1588604","volume":"12","author":"M Oshi","year":"2025","unstructured":"Oshi M, Rog C, Yan L, et al. Enhanced glycolysis is associated with aggressive tumor phenotype and worse outcomes in hepatocellular carcinoma patients. Front Med. 2025;12:1588604.","journal-title":"Front Med"},{"issue":"6","key":"19932_CR25","first-page":"3070","volume":"11","author":"M Oshi","year":"2021","unstructured":"Oshi M, Patel A, Le L, et al. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Am J Cancer Res. 2021;11(6):3070\u201384.","journal-title":"Am J Cancer Res."},{"issue":"10","key":"19932_CR26","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/cancers12102871","volume":"12","author":"M Oshi","year":"2020","unstructured":"Oshi M, Newman S, Tokumaru Y, et al. High G2M pathway score pancreatic cancer is associated with worse survival, particularly after margin-positive (R1 or R2) resection. Cancers (Basel). 2020;12(10):2871.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"19932_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40(6):609-23e6.","journal-title":"Cancer Cell."},{"issue":"18","key":"19932_CR28","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jama.2011.593","volume":"305","author":"C Hatzis","year":"2011","unstructured":"Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873\u201381.","journal-title":"JAMA."},{"key":"19932_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948601","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Hao L, Qian X, et al. Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients. Front Immunol. 2022;13:948601.","journal-title":"Front Immunol."},{"issue":"1","key":"19932_CR30","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park YH, Lal S, Lee JE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020;11(1):6175.","journal-title":"Nat Commun."},{"issue":"21","key":"19932_CR31","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-10-1265","volume":"16","author":"A Tabchy","year":"2010","unstructured":"Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16(21):5351\u201361.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"19932_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12282-025-01687-6","volume":"32","author":"Y Sota","year":"2025","unstructured":"Sota Y, Seno S, Naoi Y, et al. IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses. Breast Cancer. 2025;32(3):566\u201381.","journal-title":"Breast Cancer."},{"issue":"6","key":"19932_CR33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-12-1359","volume":"19","author":"CE Horak","year":"2013","unstructured":"Horak CE, Pusztai L, Xing G, et al. Biomarker analysis of neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res. 2013;19(6):1587\u201395.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"19932_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.14740\/wjon1732","volume":"15","author":"J Sarkar","year":"2024","unstructured":"Sarkar J, Oshi M, Satyananda V, et al. Spinster homologue 2 expression correlates with improved patient survival in hepatocellular carcinoma despite association with lymph-angiogenesis. World J Oncol. 2024;15(2):181\u201391.","journal-title":"World J Oncol."},{"issue":"2","key":"19932_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.14740\/wjon1751","volume":"15","author":"V Ramos-Santillan","year":"2024","unstructured":"Ramos-Santillan V, Oshi M, Nelson E, et al. High Ki67 gene expression is associated with aggressive phenotype in hepatocellular carcinoma. World J Oncol. 2024;15(2):257\u201367.","journal-title":"World J Oncol."},{"issue":"1","key":"19932_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.14740\/wjon1993","volume":"16","author":"P Sharma","year":"2025","unstructured":"Sharma P, Chida K, Wu R, et al. VEGFA gene expression in breast cancer is associated with worse prognosis, but better response to chemotherapy and immunotherapy. World J Oncol. 2025;16(1):120\u201330.","journal-title":"World J Oncol."},{"issue":"1","key":"19932_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.14740\/wjon1936","volume":"16","author":"G Yee","year":"2025","unstructured":"Yee G, Wu R, Oshi M, et al. Activity-regulated cytoskeleton-associated protein gene expression is associated with high infiltration of stromal cells and immune cells, but with less cancer cell proliferation and better overall survival in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast cancers. World J Oncol. 2025;16(1):16\u201329.","journal-title":"World J Oncol."},{"issue":"5","key":"19932_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.14740\/wjon2529","volume":"16","author":"G Yee","year":"2025","unstructured":"Yee G, Wu R, Ishikawa T, et al. Invasive lobular carcinoma has higher immune response than invasive ductal carcinoma in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast cancers. World J Oncol. 2025;16(5):446\u201356.","journal-title":"World J Oncol."},{"issue":"1","key":"19932_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol."},{"issue":"1\u20132","key":"19932_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1\u20132):48\u201361.","journal-title":"Cell."},{"issue":"4","key":"19932_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-30e14.","journal-title":"Immunity."},{"issue":"6","key":"19932_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst."},{"issue":"7","key":"19932_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol."},{"issue":"1","key":"19932_CR44","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s12672-025-02827-2","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Fan Y, Wang Q, et al. Tumor-infiltrating nerves: unraveling the role of cancer neuroscience in tumorigenesis, disease progression, and emerging therapies. Discov Oncol. 2025;16(1):1209.","journal-title":"Discov Oncol."},{"key":"19932_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217132","volume":"598","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yin S, Lu G, et al. The intersection of the nervous system and breast cancer. Cancer Lett. 2024;598:217132.","journal-title":"Cancer Lett."},{"issue":"3","key":"19932_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41(3):573\u201380.","journal-title":"Cancer Cell."},{"issue":"2","key":"19932_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41583-020-00407-7","volume":"22","author":"I Dalla Costa","year":"2021","unstructured":"Dalla Costa I, Buchanan CN, Zdradzinski MD, et al. The functional organization of axonal mRNA transport and translation. Nat Rev Neurosci. 2021;22(2):77\u201391.","journal-title":"Nat Rev Neurosci."},{"issue":"2","key":"19932_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mcn.2009.06.002","volume":"42","author":"CF Vogelaar","year":"2009","unstructured":"Vogelaar CF, Gervasi NM, Gumy LF, et al. Axonal mRNAs: characterisation and role in the growth and regeneration of dorsal root ganglion axons and growth cones. Mol Cell Neurosci. 2009;42(2):102\u201315.","journal-title":"Mol Cell Neurosci."},{"issue":"8060","key":"19932_CR49","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-025-08735-3","volume":"640","author":"V Thiel","year":"2025","unstructured":"Thiel V, Renders S, Panten J, et al. Characterization of single neurons reprogrammed by pancreatic cancer. Nature. 2025;640(8060):1042\u201351.","journal-title":"Nature."},{"issue":"7","key":"19932_CR50","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.humpath.2014.02.009","volume":"45","author":"A Olar","year":"2014","unstructured":"Olar A, He D, Florentin D, et al. Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol. 2014;45(7):1358\u201364.","journal-title":"Hum Pathol."},{"key":"19932_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2016.02.001","volume":"52","author":"D He","year":"2016","unstructured":"He D, Manzoni A, Florentin D, et al. Biologic effect of neurogenesis in pancreatic cancer. Hum Pathol. 2016;52:182\u20139.","journal-title":"Hum Pathol."},{"issue":"8059","key":"19932_CR52","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-025-08591-1","volume":"640","author":"X Zhi","year":"2025","unstructured":"Zhi X, Wu F, Qian J, et al. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis. Nature. 2025;640(8059):802\u201310.","journal-title":"Nature."},{"key":"19932_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105325","volume":"108","author":"OV Bjornstad","year":"2024","unstructured":"Bjornstad OV, Carrasco M, Finne K, et al. Global and single-cell proteomics view of the co-evolution between neural progenitors and breast cancer cells in a co-culture model. EBioMedicine. 2024;108:105325.","journal-title":"EBioMedicine."},{"key":"19932_CR54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/1471-2407-14-484","volume":"14","author":"Q Zhao","year":"2014","unstructured":"Zhao Q, Yang Y, Liang X, et al. The clinicopathological significance of neurogenesis in breast cancer. BMC Cancer. 2014;14:484.","journal-title":"BMC Cancer."},{"issue":"16_suppl","key":"19932_CR55","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.1200\/JCO.2024.42.16_suppl.11016","volume":"42","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, Ballman KV, Holmes MD, et al. Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502. J Clin Oncol. 2024;42(16_suppl):11016.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19932-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:25:50Z","timestamp":1792207550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19932-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["19932"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19932-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB is a co-founder of Channavix Therapeutics, LLC and Mimetic Medicines, INC. All other authors have no related conflict of interests to declare.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}